RIBOTAC-mediated degradation of hsa-microRNA-301a-3p suppresses TNBC bone metastasis
Science Advances · 2026
DOI: 10.1126/sciadv.aeh7999 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Wei Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200025, China. Hauptthemen laut MEDLINE: MicroRNAs, Bone Neoplasms, Triple Negative Breast Neoplasms, Endoribonucleases. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National key R&D program of China, National Natural Science Foundation of China, Shanghai Shuguang Program.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is an aggressive subtype with a high propensity for bone metastasis and limited treatment options. Although many proteins drive metastasis, most remain inaccessible to conventional small-molecule drugs due to lack of suitable binding sites, prompting interest in upstream RNA regulators. Using integrative bioinformatics and machine learning, we identified hsa-microRNA-301a-3p as a central regulator of TNBC bone metastasis. However, current nucleic acid–based therapies are limited by instability and inefficient delivery. To overcome these challenges, we designed a ribonuclease-targeting chimera (RIBOTAC) that recruits endogenous RNase L to degrade the primary transcript pri-microRNA-301a. The resulting RIBOTAC efficiently reduced hsa-microRNA-301a-3p levels, restored NEDD4L expression, and promoted degradation of the oncogenic protein YAP, thereby suppressing TNBC bone metastasis. These findings identify hsa-microRNA-301a-3p as a key driver and demonstrate RNA-targeted degradation as a therapeutic strategy in TNBC bone metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200025, China.
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine…
- State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100700, China.
- School of Pharmacy, Naval Medical University, Shanghai, 200433, China.
ORCID-Profile: Wei Zhou, Jinmei Jin, Xiao-Hui Liang, Yue Yan, Qingyi Xiong, Dong Lu, Hongzhuan Chen, Ye Wu, Wei-Dong Zhang, Xin Luan
Förderung
- National key R&D program of China
- National Natural Science Foundation of China
- Shanghai Shuguang Program
- Shanghai Sailing Program
- CAMS Innovation Fund for Medical Sciences
- Key project at central government level: The ability establishment of sustainable use for valuable Chinese medicine resources
- Innovative Drug Research and Development-National Science and Technology Major Project
- High level Key Discipline of National Administration of Traditional Chinese Medicine
Zitieren
APA
Zhou, W., Jin, J., Liang, X. H., Yan, Y., Xiong, Q., Lu, D., Chen, H., Wu, Y., Zhang, W. D., & Luan, X. (2026). RIBOTAC-mediated degradation of hsa-microRNA-301a-3p suppresses TNBC bone metastasis. Science Advances. https://doi.org/10.1126/sciadv.aeh7999
Vancouver
Zhou W, Jin J, Liang XH, Yan Y, Xiong Q, Lu D, et al. RIBOTAC-mediated degradation of hsa-microRNA-301a-3p suppresses TNBC bone metastasis. Science Advances. 2026. doi:10.1126/sciadv.aeh7999
BibTeX
@article{Zhou2026,
author = {Zhou, Wei and Jin, Jinmei and Liang, Xiao-Hui and Yan, Yue and Xiong, Qingyi and Lu, Dong and Chen, Hongzhuan and Wu, Ye and Zhang, Wei-Dong and Luan, Xin},
title = {RIBOTAC-mediated degradation of hsa-microRNA-301a-3p suppresses TNBC bone metastasis},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aeh7999}
}
EUVIMED